Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
LONDON, Aug. 4, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
The Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why companies enter distribution deals.
The majority of deals are multicomponent whereby the licensor offers a right to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of distribution dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in distribution as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of distribution deals. The chapter includes numerous case studies to enable understanding of both pure distribution deals and multicomponent deals where distribution forms a part.
Chapter 4 provides a review of the leading distribution deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most active bigpharma and bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of distribution deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of distribution deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2009 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.
In addition the report includes a comprehensive listing of all distribution deals announced since 2009.
Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2009.
Report scope
Distribution Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.
Distribution Partnering Terms and Agreements includes:
Trends in distribution dealmaking in the biopharma industry since 2009
Analysis of distribution deal structure
Case studies of real-life distribution deals
Access to over 2,000 distribution deals documents
The leading distribution deals by value since 2009
Most active distribution dealmakers since 2009
The leading distribution partnering resources
In Distribution Partnering Terms and Agreements, the available deals are listed by:
Company A-Z
Headline value
Stage of development at signing
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
The Distribution Partnering Terms and Agreements report provides comprehensive access to available records for over 1,900 distribution deals, including contract documents where available. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Number of pages:
The report comprises of 2,168 pages including appendices
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in distribution dealmaking
2.1. Introduction
2.2. Definition of distribution deals
2.3. Trends in distribution deals since 2009
2.3.1. Attributes of pure distribution deals
2.3.2. Attributes of distribution in multi-component deals
2.4 . Aligning partners to make the distribution agreement work
Chapter 3 – Overview of distribution deal structure
3.1. Introduction
3.2.Distribution agreement structure
3.3. Example distribution agreements
3.3.1. Case study 1: Zeltiq Aesthetics – Advance Medical – 18 March 2011
3.3.2. Case study 2: QLT – ASD Speciality Healthcare – January 2010
3.4 Distribution rights as part of a wider alliance agreement
3.4.1. Case study 1: Caleco Pharma – Natac Biotech – March 2010
3.4.2. Case study 2: Purdue Pharma – Transcept Pharmaceuticals – July 2009
Chapter 4 – Leading distribution deals
4.1. Introduction
4.2. Top distribution deals by value
4.3. Most active distribution dealmakers
4.4. Big pharma distribution deal activity
4.5. Big biotech distribution deal activity
Chapter 5 – Big pharma distribution deals
5.1. Introduction
5.2. How to use distribution deals
5.3. Big pharma distribution partnering company profiles
Abbott
Actavis
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Eisai
Eli Lilly
Forest Laboratories
Fresenius
Galderma
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mylan
Novartis
Novo Nordisk
Pfizer
Purdue
Ranbaxy Laboratories
Roche
Sanofi
Shionogi
Shire
Takeda
Teva
UCB
Valeant
Chapter 6 – Big biotech distribution deals
6.1. Introduction
6.2. How to use big biotech partnering deals
6.3. Big biotech distribution partnering company profiles
Actelion
Anika Therapeutics
Biocon
BioMarin Pharmaceuticals
Cangene
Dendreon
Elan
Enzo Biochem
Ipsen
LFB Group
NPS Pharmaceuticals
Optimer
Regeneron Pharmaceuticals
SciClone Pharmaceuticals
Shire
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
United Therapeutics
ViroPharma
Chapter 7 – Distribution contracts directory
7.1. Introduction
7.2. By Company A-Z
7.3. By therapeutic target
Anaesthetics
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Gynaecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Pediatrics
Psychiatry
Public health
Respiratory
7.4 By technology type
Antibiotics
Assays
Biological compounds
Biomarkers
Biomaterials
Blood products
Cell culture
Devices
Diagnostics
Discovery tools
Drug delivery
Enabling technology
Enviromental
Equipment
Facilities
Genomics
Implant
Industrial chemicals
In vitro models
Nanotechnology
Natural product
Packaging
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Regenerative medicine
Research services
Research supplies
Screening
Small molecules
Software tools
Stem cells
Vaccines
7.5. By industry sector target
Academic
Animal Health
Bigbiotech
Bigpharma
Biotech
Consumer health
Drug delivery
Medical device
Diagnostic
Generic pharma
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form – Reports
See accompanying volume for the following appendices
Appendix 1 – Distribution dealmaking companies A-Z
Appendix 2 – By stage of development
Appendix 3 – By therapeutic target
Appendix 4 – By technology type
Appendix 5 – Distribution dealmaking references
Appendix 6 – Resources
Appendix 7 – Deal type definitions
Appendix 8 – Resources
TABLE OF FIGURES
Figure 1: Definition of distribution
Figure 2: Trends in distribution deal announcements, 2009-2014
Figure 3: Distribution deals signed at each phase of development, 2009-2014
Figure 4: Issues in implementing distribution agreements
Figure 5: Distribution agreements – what should a contract include?
Figure 6: Components of the distribution deal structure
Figure 7: Top distribution deals by value since 2009
Figure 8: Most active distribution dealmakers 2009-2014
Figure 9: Big pharma – top 50 – distribution deals 2009 to 2014
Figure 10: Big pharma distribution deal frequency - 2009 to 2014
Figure 11: Big biotech – distribution deals 2009 to 2014
Figure 12: Big biotech distribution deal frequency - 2009 to 2014
Read the full report:
Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article